Abstract:BACKGROUND:Tumor cells produce vascular endothelial growth factor (VEGF) which interact with the membrane or cytoplasmic VEGF receptors (VEGFRs) to promote cell growth in an angiogenesis-independent fashion. Apatinib, a highly selective VEGFR2 inhibitor, is the only effective drug for patients with terminal gastric cancer (GC) who have no other chemotherapeutic options. However, its treatment efficacy is still controversy and the mechanism behind remains undetermined. In this study, we aimed to investigate the role of autocrine VEGF signaling in the growth of gastric cancer cells and the efficacy of Apatinib treatment.METHODS:The expression of phosphor VEGFR2 in gastric cancer cell lines was determined by real-time PCR, immunofluorescence, and Western blot. The gastric cancer cells were administrated with or without recombination human VEGF (rhVEGF), VEGFR2 neutralizing antibody, U73122, SU1498, and Apatinib. The nude mice were used for xenograft tumor model.RESULTS:we found that autocrine VEGF induced high VEGFR2-expression, promoted phosphorylation of VEGFR2, and further enhanced internalization of pVEGFR2 in gastric cancer cells. The autocrine VEGF was self-sustained through increasing VEGF mRNA and protein expression. It exerted pro-proliferative effect through a PLC-ERK1/2 dependent pathway. Furthermore, we demonstrated that in VEGFR2 overexpressing gastric cancer cells, Apatinib inhibited cell proliferation in vitro and delayed xenograft tumor growth in vivo. However, these effects were not observed in VEGFR2 low expressing gastric cancer cells.CONCLUSION:These results suggested that autocrine VEGF signaling promotes gastric cancer cell proliferation and enhances Apatinib treatment outcome in VEGFR2 overexpression gastric cancer cells both in vitro and in vivo. This study would enable better stratification of gastric cancer patients for clinical treatment decision.

Expression of a Functional VEGFR-1 in Tumor Cells is a Major Determinant of Anti-Plgf Antibodies Efficacy

Tumor Cell-Derived Placental Growth Factor Sensitizes Antiangiogenic and Antitumor Effects of Anti-Vegf Drugs

PlGF-induced VEGFR1-dependent Vascular Remodeling Determines Opposing Antitumor Effects and Drug Resistance to Dll4-Notch Inhibitors

Vascular Endothelial Growth Factor-Dependent Spatiotemporal Dual Roles of Placental Growth Factor in Modulation of Angiogenesis and Tumor Growth

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

Expression of Placenta Growth Factor (plgf) in Non-Small Cell Lung Cancer (NSCLC) and the Clinical and Prognostic Significance.

Genetic Inhibition Of Vascular Endothelial Growth Factor Receptor-1 Significantly Inhibits The Migration And Proliferation Of Leukemia Cells And Increases Their Sensitivity To Chemotherapy

PlGF: a multitasking cytokine with disease-restricted activity

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models

Placenta Growth Factor-1 Exerts Time-Dependent Stabilization of Adherens Junctions Following VEGF-Induced Vascular Permeability

Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway

PLGF Regulates Crosstalk Between Non-Small Cell Lung Cancer Cells and Tumor-Associated Macrophages in Cancer Vascularization and Growth

Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

Autocrine VEGF Signaling Promotes Cell Proliferation Through a PLC-dependent Pathway and Modulates Apatinib Treatment Efficacy in Gastric Cancer.

Placenta Growth Factor, PLGF, Influences the Motility of Lung Cancer Cells, the Role of Rho Associated Kinase, Rock1

Tumor-derived Vascular Endothelial Growth Factor (Vegf)-a Facilitates Tumor Metastasis Through the VEGF-VEGFR1 Signaling Pathway.

Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells.

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway

Placental growth factor stabilizes VEGF receptor-2 protein in retinal pigment epithelial cells by downregulating glycogen synthase kinase 3 activity